265 related articles for article (PubMed ID: 38115743)
1. Advances in DNA damage response inhibitors in colorectal cancer therapy.
Yu Y; Jia H; Zhang T; Zhang W
Acta Biochim Biophys Sin (Shanghai); 2024 Jan; 56(1):15-22. PubMed ID: 38115743
[TBL] [Abstract][Full Text] [Related]
2. DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.
Solier S; Zhang YW; Ballestrero A; Pommier Y; Zoppoli G
Curr Cancer Drug Targets; 2012 May; 12(4):356-71. PubMed ID: 22385513
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers.
Wilsker DF; Barrett AM; Dull AB; Lawrence SM; Hollingshead MG; Chen A; Kummar S; Parchment RE; Doroshow JH; Kinders RJ
Clin Cancer Res; 2019 May; 25(10):3084-3095. PubMed ID: 30792217
[TBL] [Abstract][Full Text] [Related]
4. Targeting the DNA Damage Response in Cancer.
O'Connor MJ
Mol Cell; 2015 Nov; 60(4):547-60. PubMed ID: 26590714
[TBL] [Abstract][Full Text] [Related]
5. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
Aktas BY; Guner G; Guven DC; Arslan C; Dizdar O
Expert Rev Anticancer Ther; 2019 Jul; 19(7):589-601. PubMed ID: 31181965
[No Abstract] [Full Text] [Related]
6. Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.
Catalano F; Borea R; Puglisi S; Boutros A; Gandini A; Cremante M; Martelli V; Sciallero S; Puccini A
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326540
[TBL] [Abstract][Full Text] [Related]
7. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy.
Yang Y; Meng WJ; Wang ZQ
Front Biosci (Landmark Ed); 2023 Apr; 28(4):69. PubMed ID: 37114536
[TBL] [Abstract][Full Text] [Related]
9. Differences in DNA damage repair gene mutations between left- and right-sided colorectal cancer.
Huang W; Li W; Xu N; Li H; Zhang Z; Zhang X; He T; Yao J; Xu M; He Q; Guo L; Zhang S
Cancer Med; 2023 May; 12(9):10187-10198. PubMed ID: 37096801
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Therapeutic Application of DNA Damage Response Inhibitors against Cancer.
Fernandes SG; Shah P; Khattar E
Anticancer Agents Med Chem; 2022; 22(3):469-484. PubMed ID: 34102988
[TBL] [Abstract][Full Text] [Related]
11. Breaking the DNA damage response to improve cervical cancer treatment.
Wieringa HW; van der Zee AG; de Vries EG; van Vugt MA
Cancer Treat Rev; 2016 Jan; 42():30-40. PubMed ID: 26643553
[TBL] [Abstract][Full Text] [Related]
12. Single-cell dissection reveals the role of DNA damage response patterns in tumor microenvironment components contributing to colorectal cancer progression and immunotherapy.
Shen X; Mo S; Wang Y; Lin L; Liu Y; Weng M; Gu W; Nakajima T
Genes Cells; 2023 May; 28(5):348-363. PubMed ID: 36811212
[TBL] [Abstract][Full Text] [Related]
13. Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.
Zhang CM; Lv JF; Gong L; Yu LY; Chen XP; Zhou HH; Fan L
Int J Environ Res Public Health; 2016 Sep; 13(9):. PubMed ID: 27618077
[TBL] [Abstract][Full Text] [Related]
14. DNA damage response inhibitors: An avenue for TNBC treatment.
Jin J; Tao Z; Cao J; Li T; Hu X
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188521. PubMed ID: 33556453
[TBL] [Abstract][Full Text] [Related]
15. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
16. Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer.
Durinikova E; Reilly NM; Buzo K; Mariella E; Chilà R; Lorenzato A; Dias JML; Grasso G; Pisati F; Lamba S; Corti G; Degasperi A; Cancelliere C; Mauri G; Andrei P; Linnebacher M; Marsoni S; Siena S; Sartore-Bianchi A; Nik-Zainal S; Di Nicolantonio F; Bardelli A; Arena S
Clin Cancer Res; 2022 Sep; 28(17):3874-3889. PubMed ID: 35881546
[TBL] [Abstract][Full Text] [Related]
17. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.
Mao X; Lee NK; Saad SE; Fong IL
Transl Lung Cancer Res; 2024 Feb; 13(2):375-397. PubMed ID: 38496700
[TBL] [Abstract][Full Text] [Related]
18. DNA damage response and repair in pancreatic cancer development and therapy.
Rahnamay Farnood P; Danesh Pazhooh R; Asemi Z; Yousefi B
DNA Repair (Amst); 2021 Jul; 103():103116. PubMed ID: 33882393
[TBL] [Abstract][Full Text] [Related]
19. The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer.
Mauri G; Arena S; Siena S; Bardelli A; Sartore-Bianchi A
Ann Oncol; 2020 Sep; 31(9):1135-1147. PubMed ID: 32512040
[TBL] [Abstract][Full Text] [Related]
20. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.
Huang JL; Chang YT; Hong ZY; Lin CS
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
